

Migraine - Prophylactic and Acute Migraine Treatments

An analysis of pharmacological and non-pharmacological options

CURT HENDRIX, M.S., C.C.N., C.N.S.

Evidence-Based Use of Supplements

ABSTRACT

The goal of this paper is to provide a comprehensive assessment on the data around migraine and relevant therapeutics. Here, we cover pros and cons of traditional treatments and analyze the published peer-reviewed clinical data supporting the use of non-pharmacological options.

Migraines affect at least 1 in 10 people worldwide, and its prevalence is on the rise.¹ According to the World Health Organization (WHO), migraine ranks as the 2nd most disabling neurological condition and the 3rd most prevalent medical condition in the world.^{2,3} Though migraines affect approximately 15% of adults in the United States, only about one quarter of those with chronic migraines receive an accurate diagnosis, and of those who do, fewer than 50% are provided with acute or preventative treatments.^{4,5} Also problematic is that there is no cure for migraines, and for more than 90% of those who suffer the condition, their migraines interfere with some combination of their work, education, and social activities.⁶ A longitudinal study on the impact of migraines revealed that more than half of people who suffer from migraines participated in fewer family activities and believed they would be better parents and partners if they did not have migraines.⁷ Approximately 33% of these patients also reported worry that their migraines could compromise their long-term financial security.

What are Migraines?

A chronic neurological disorder, migraine involves moderate or severe head pain that is often described as throbbing and worsened by head movement or physical activity.⁴ These headaches may be unilateral and may change sides and often involve the posterior cervical and trapezius regions of the head.^{4,8} However, migraines can also be bilateral, in which case they may be mistaken for tension-type headaches.⁹ The headaches are often accompanied by other symptoms, such as sensitivity to light and sound, dizziness, tinnitus, gastrointestinal disturbances, cognitive impairment, and cutaneous allodynia - or the presence of pain in response to non-painful stimuli being applied to the skin.^{4,10}

The specific symptoms that may arise with migraines include:¹¹⁻¹⁷

- Photophobia
- Phonophobia
- Visual aura
- Neck pain
- Dizziness
- Cutaneous allodynia
- Non-aura visual symptoms
- Vomiting
- Hyperosmia or osmophobia
- Diarrhea

What are the Classic Symptoms?

Migraines are characterized by premonitory and postdromal symptoms. Unlike many other conditions, acute migraines are often preceded by premonitory symptoms that last for hours or days.¹⁸ While the most common of these symptoms are fatigue, neck stiffness, and trouble concentrating, there is a wide variety of other symptoms that may be experienced. These symptoms include psychological symptoms, such as anxiety or depression, as well as lacrimation, photophobia, diarrhea, increased urination, food cravings, and nausea.¹⁹

Once the migraine headache resolves, 80% of migraine sufferers undergo a postdromal phase that can potentially last for days.²⁰⁻²³ Symptoms during this phase include fatigue, photophobia, nausea, irritability, and problems with concentration.⁴

Migraines can occur at any time, but they often occur soon after waking or early in the morning.^{24,25} The median time for a migraine headache to reach its peak pain intensity is 1 hour, though the median duration is 24 hours.⁸ There are several specific types of migraines, including migraines without head pain, the details of which are beyond the scope of this review. However, this resource offers a more in-depth discussion of each type of headache.²⁶

What are the Risk Factors for Migraines?

Genetics

Migraines run in families. For those with a parent who suffers from migraines, there is a 40% chance that they too will develop migraines.⁴ If both parents have migraines, that risk increases to 75%. Research into the genetic contributions to migraines are providing more information on the specific genes that may be involved in migraines. Next-generation sequencing, for instance, will likely lead to the discovery of causal genes and variants.²⁷ Nonetheless, it is clear that the genetic underpinnings of migraine disorders are complex, much like their pathogenesis.²⁷

Age

Early and middle adulthood appear to be the most likely time to experience migraines, though the precise ages during which one is most likely to suffer from migraines depends on how researchers group age. For instance, it has been reported that those between the ages of 25 and 55 are most

likely to suffer from migraines and also that 18- to 44-year-olds have the highest prevalence of migraines.^{4,28} However, it seems clear that prevalence hits a peak in people's 40s.⁵

Sex and Race

The lifetime prevalence of migraine is estimated at 33% for women, and 13% in men, though before puberty, migraines occur slightly more frequently in boys than in girls.^{4,29} Data from 2015 suggest that migraines occur most in American Indian and Alaska Native populations, with a prevalence of more than 18% in these groups. Asians were found to suffer from migraines less than not only these groups but also whites, blacks, and Hispanics. The prevalence amongst Asians was found to be approximately 11%.

Other Factors

Migraine prevalence is over 21% in those who are unemployed and nearly 20% in those with an annual family income of less than \$35,000.²⁸ These associations do not, however, provide any information on if these conditions may cause migraines or vice versa. Interestingly, neurologists have been found to suffer from migraines 2 to 3 times more frequently than the general population.³⁰ These findings may be due to better recognition amongst neurologists of the symptoms of migraine.

How are Migraines Conventionally Treated, and are Treatments Safe and Effective?

Pharmacological Interventions

Simple Analgesics

People with mild to moderate migraines are recommended to use mild analgesics like acetaminophen as a first approach to migraines because these drugs offer several relative advantages when compared with other migraine drugs. For instance, they tend to be effective in certain patients, they are less costly, and they are not as likely to lead to adverse side effects.⁵

Most migraine sufferers use simple analgesics, but many of these patients use a step-care approach, where they move on to migraine-specific drugs when the pain becomes severe enough to warrant something stronger than a simple analgesic.³¹ Acetaminophen is also often used in combination with NSAIDs and caffeine for a stronger response.³²

Acetaminophen is recommended at doses ranging from 1000 milligrams (mg) to 4000 mg taken every 4 hours.³² The downside to acetaminophen is that randomized controlled trials have shown that its efficacy is mainly limited to the treatment of mild to moderate migraines.^{33,34} Those with more severe migraines may therefore get little relief from acetaminophen and be forced to rely on other interventions.

In addition to the potential lack of adequate efficacy, acetaminophen can lead to adverse side effects. For instance, chronic use of acetaminophen enhances the risk for gastrointestinal bleeding and increases in systolic blood pressure.³⁵ Other risks associated with asthma, kidney injury, liver damage, and cardiovascular disease are also possible, and ongoing research is exploring the effects of in utero exposure to this drug. For these reasons, acetaminophen may not offer a safe and practical long-term solution for migraine sufferers.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Non-steroidal anti-inflammatory drugs (NSAIDs) are often used in the acute management of migraines, with some of the most effective NSAIDs being ibuprofen (400 to 2400 mg every 4 hours), acetylsalicylic acid (ASA) (975-100 mg every 4-6 hours), naproxen sodium (500-1375 mg twice a day), and diclofenac potassium (50-150 mg as a single dose for an attack or 3-4 times per day).³²

Ibuprofen is used more often than other NSAIDs for migraine management, likely due to its relatively good efficacy, low cost, and availability.³² It is also thought to produce less gastric irritation than ASA. Comprehensive reviews of the efficacy and safety of naproxen sodium in the acute treatment of migraines have shown it to be more effective than placebo in treating moderate to severe migraines but has also demonstrated that it is associated with more adverse events.³⁶

Despite their frequent use, NSAIDs are associated with adverse side effects, including cardiovascular, cerebral, gastrointestinal, hepatic, pulmonary, and renal complications.³⁷ Troublingly, some pathologies that present asymptotically can be life threatening.³⁸ NSAIDs are also associated with a high rate of adverse drug reactions (ADRs) and are responsible for 30% of hospitalizations that occur due to ADRs.³⁹

Ergots

Ergots and ergot derivatives began being used to treat migraines more than a century ago. However, the use of ergots has been controversial due to the harmful side effects associated with them and challenges with balancing efficacy and safety.⁴⁰ While ergot formulations have been developed that have more tolerable side effects, including the orally inhaled dihydroergotamine, concerns about vasoconstrictive effects of ergots persist.^{41,42} In addition to the dangerous adverse effects, other adverse side effects frequently occur as well. Nausea is the most common adverse side effect, and light headedness and leg cramps are also common.⁴³

Triptans

Triptans, which are highly selective serotonin receptor agonists for the 5-HT_{1B} and 5-HT_{1D} receptors, with some relevant activity at the 5-HT_{1F} receptor, are considered first-line drugs for people with moderate to severe migraines.³² They are also indicated for menstruation-related migraines.⁵ Though effective in treating headaches, they are not used preventatively.

The triptans that have good evidence for efficacy in treating acute migraines are almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan.³² There is some debate, however, about which triptan is the best to use to combat migraines.⁴⁴ Dosing can also be complicated. Both oral and non-oral formulations are available, and determining dosage is often a trial-and-error process.⁴ In addition, repeat dosing may be required after the initial use of triptans.

Triptans can cause vasoconstriction by binding to systemic blood vessel receptors as well as both intracranial and extracranial blood vessels, which likely contributes to their influence on migraines.⁴ Though effective, an analysis of the safety of triptans by the U.S. Food and Drug Administration (FDA), found that triptan is associated with aneurysms, artery dissections, and pregnancy-related vascular events. Triptans can also lead to an increase in migraine frequency

if overused, as neural adaptations that occur with triptans can increase one's sensitivity to migraine triggers.⁴⁵ Given the risks, triptans are contraindicated for patients with severe hypertension or with a history of cerebrovascular disease.^{4,5} Triptans have also been reported to lead to fetal death and intrauterine growth retardation in those who are exposed to triptans during pregnancy and are thus not always considered a good option for pregnant women.⁴⁶

Beta-Blockers

Beta-blockers whose efficacy is considered well established for preventing migraines include metoprolol, propranolol, and timolol.⁵ Atenolol and nadolol are also considered likely to be effective, but the evidence is not as high as for the former drugs. Nebivolol may be effective but has not been as extensively investigated as the other beta-blockers. beta-blockers with intrinsic sympathetic activity, such as acebutolol, alprenolol, oxyprenolol, and pindolol do not appear to have the prophylactic value in migraine that other beta-blockers have.⁴⁷

Some research suggests that when used in combination with behavioral therapy, beta-blockers are particularly effective for improving outcomes related to frequent migraines.⁴⁸ However, a recent systemic review and meta-analysis found that the trials investigating the effectiveness of beta-blockers in chronic migraines are limited in terms of the evidence they provide on the benefit of these drugs. In addition to questions of efficacy for chronic migraines, the value of beta-blockers may also be limited by potential side effects, the most common of which appear to affect the central nervous system.^{49,50}

Antiepileptic Drugs

Migraines and epilepsy occur via similar mechanisms that involve overexcitability in neocortical cells.⁵¹ It is thus not surprising that antiepileptic drugs that target excessive neuronal activity can be effective in migraine treatment.

Divalproex sodium, sodium valproate, and topiramate are thought to be effective preventative treatments for migraines.⁵ Carbamazepine and lamotrigine are other antiepileptic drug with some evidence for efficacy in combatting migraines.^{5,52} Despite some reports that gabapentin can be effective in migraines, a recent Cochrane review found that there is insufficient evidence for the use of this antiepileptic in migraines.⁵³

Antiepileptic drugs likely work through several mechanisms, affecting neurotransmitter receptors, neurotransmitter metabolism, and ion channels to reduce excitability and potentially protect neurons.⁵⁴ These drugs, however, are associated with unwanted side effects, which appear to be particularly common in migraine patients despite the low doses of antiepileptics used in migraines.⁵⁵

For instance, topiramate has been shown to commonly lead to altered taste, diarrhea, paresthesias, and somnolence in migraine patients.⁵⁶ In addition, several antiepileptics can lead to adverse outcomes in infants of mothers taking these drugs.⁵² This risk is high enough with valproate that it is not recommended that women of childbearing potential use this antiepileptic. The most common adverse effects of antiepileptic drugs, however, appear to be those that affect the central nervous system and specifically lead to psychiatric and behavioral changes.^{57–59}

Antidepressants

Unlike depression, migraines respond to drugs that act peripherally. However, meaningful overlap exists between

depression and migraines, and both conditions are associated with reduced levels of serotonin.^{60,61} Antidepressants, particularly those that work through the serotonergic system have thus been explored for their potential value in migraines.

Stress often triggers migraines, so the potential for antidepressants to lower perceived stress could contribute to the value of these drugs in improving migraine symptoms.⁶² Research into this issue has shown that antidepressants may be a reasonable second or third line prophylactic therapy in migraine patients who have not responded adequately to other medications.⁶³ In the case that an antidepressant approach is taken, amitriptyline monotherapy is recommended as the first choice.

Unfortunately, for those who suffer from both depression and migraines, one antidepressant is often insufficient for improving symptoms of both disorders.⁶⁴ Complicating this problem is that antidepressants taken in combination with other migraines medications can be dangerous and can specifically increase the risk of serotonin syndrome, which occurs when serotonin levels get too high.⁶⁵ These issues are compounded by the adverse effects associated with antidepressants taken in any context, which include but are not limited to sleep disturbances, weight changes, sexual dysfunction.⁶⁶

Monoclonal Antibodies

In recent years, monoclonal antibodies, namely gepants, have begun being used in migraine prevention for treatment-resistant patients to facilitate the binding to and inhibition of calcitonin gene-related peptide (CGRP), a peptide known to be involved in migraines.^{67–69} A meta-analysis covering data from nearly 9,000 patients has found that different forms of these antibodies are more effective than placebo in reducing the frequency of adult migraines.⁷⁰ Another meta-analysis showed that in addition to helping reduce the number of days each month that migraines were experienced, monoclonal antibodies were also a safe way to prevent episodic migraines.⁷¹

Researchers have also investigated the impact of monoclonal antibodies against other migraine treatment options and found that monoclonal antibodies may be more promising than other migraine interventions. A meta-analysis comparing the impact of monoclonal antibodies versus botulinum toxin in migraine found that CGRP monoclonal antibody was slightly more efficacious and safer than botulinum toxin for preventing chronic migraines.⁷² Other research has shown that CGRP monoclonal antibodies appear to be more favorable from a benefit-risk perspective than other established treatments for migraines, but researchers highlight that more comparative research is needed to understand the relative risks and benefits of monoclonal antibodies versus other treatments for migraines.⁷³ Indeed, considerable adverse effects from injectable CGRP monoclonal antibodies have been observed and demand more study before this treatment option is widely disseminated.⁷⁴

How Can We Improve Migraine Prevention and Treatment?

The prevalence of migraine disorder has remained largely unchanged over the past two decades.²⁸ There is thus a need to improve our ability to prevent and treat migraines beyond what is possible with conventional treatments. Research into the effects of non-pharmacological interventions offer clues into how we can develop more effective prophylactic and acute treatments for migraines.

Non-Pharmacological Interventions

Pharmacological approaches to migraine remain limited, and the medications used to treat migraines cannot be used continuously. Even simple analgesics like the NSAID paracetamol are not recommended to be used more than 15 days each month, and combination analgesics as well as triptan and ergot drugs should not be used more than 10 days each month.^{4,75} In addition, medication overuse is a well-established cause of headache and can thus diminish the value of pharmacological interventions meant to address migraines.^{76,77} Non-pharmacological interventions are thus critical for the management of migraines. The research related to some of these approaches are summarized below.

Diet

Diet is implicated in migraines, and it has been suggested that the inflammation that occurs due to dietary choices plays a role in the relationship between diet and migraines.⁷⁸ There are known dietary triggers for migraines, most of which involve missed meals.⁷⁹ Some people, however, experience migraines in response to specific foods. The most common foods to lead to migraines are caffeine, additives, and artificial sweeteners.⁵

Several specific diets have been shown to provide benefits for migraineurs including ketogenic, low-fat, modified Atkins, high-folate, and high omega-3/low omega-6 diets.⁸⁰ The mechanisms by which these diets may improve migraines is not well understood, but it has been proposed that some of these diets could reduce inflammation, provide neuroprotection, improve mitochondrial function, or compensate for dysfunction in the serotonergic system.

It is important to note that diets that are effective in migraines appear to in many instances work based on comorbidities. For instance, consuming less sodium appears to reduce headache occurrence in older people with hypertension, while weight loss diets are effective in obese patients.^{80–82}

Exercise

As with many disorders, there is evidence to show that exercise can be beneficial for migraines and has been posed as an option for preventing migraines in those who do not respond to or who do not want to take daily medications.^{83,84} In particular, regular physical activity can help to reduce migraines frequency.⁸⁵

It has been proposed that the mechanism through which exercise can decrease the frequency of migraines is by raising the threshold for which migraines tend to be triggered.⁸³ Cardiovascular exercise for instance may modulate pain mechanisms to alter the experience of migraines.⁸⁶ Other research has shown that there are several variables that impact the likelihood that a migraineur will benefit from exercise, including fitness level, psychological states, and neurochemical factors.⁸⁷

While getting enough of exercise may reduce the total number of days in which migraines occur, a recent review on the link between exercise and migraines found that there is not enough evidence to determine if migraine intensity or migraine duration may be impacted by exercise.⁸⁶ It is also important to note that though exercise may be protective in migraine, they can also act as triggers for migraine attacks.⁸⁵

Psychotherapy

There are several psychological interventions used to manage migraines.⁸⁹ The literature on the impact of these interventions on migraines suggest that they do not affect the frequency of migraines. Whether psychological interventions may impact the experience or severity of migraines is unclear.

A review of non-pharmacological interventions for migraines found that there is strong evidence to support the use behavioral therapy as an adjunctive treatment to prevent migraine attacks.⁹⁰ Advantages of behavioral approaches for intervening with migraines include that behavioral methods are not associated with the adverse side effects that are associated with drug treatments and that these approaches can leverage modern technological capabilities to deliver new and innovative intervention strategies.^{5,89} Nonetheless, the benefits of behavioral therapies are often recognized when used in combination with medications.⁹¹

Clinically Studied Dietary Supplements

Magnesium

The United States Headache Consortium (USHC) has suggested magnesium as a microelement for preventing migraines.⁹² Magnesium is the second most common intracellular cation in tissues that influence neurochemical processes and acts as a cofactor for more than 350 enzymes.⁹³

Magnesium helps to maintain the electric potential of cells, and magnesium deficiencies can therefore lead to neurological problems.⁹⁴ Low magnesium in both serum and cerebrospinal fluid is associated with migraines. Current data suggests that up to half of all patients suffering an acute migraine have lowered levels of ionized magnesium.⁹⁵ Based on these observations, magnesium has long been used both prophylactically and as treatment for migraines.

The excessive excitability of neurons in migraines occurs in large part due to glutamate and NMDA receptors with which glutamate interacts to activate neurons. Magnesium has the potential to block NMDA receptors – a property that has been shown to affect pain transmission that is associated with the excessive excitability observed in neurons in migraineurs. Because it can block these receptors, magnesium has been hypothesized to provide therapy for migraines. Supporting this idea were the results of a placebo-controlled double-blind randomized study on the prophylactic use of oral magnesium, which showed that doses of 600 mg and lower offered prophylactic value for these patients.⁹⁶

A meta-analysis on the effects of intravenous magnesium in migraine has shown that intravenous magnesium can within 15 minutes alleviate acute migraine attacks.⁹⁷ Further, results show that following 24 hours of infusion combined with oral magnesium, both the frequency and intensity of migraine are reduced.

Riboflavin

Riboflavin, also known as vitamin B2, has been shown to play a role in migraines – particularly in migraine prevention. A recent review of the literature found that riboflavin supplements could reduce both the frequency and duration of migraines in adults without any serious side effects.⁹⁸

One study that specifically addressed the value of riboflavin for prophylactic use against migraines showed that riboflavin treatment significantly reduced the frequency of headaches.⁹⁹ Migraine patients took 400 mg riboflavin capsules each day, and the average number of days they spent suffering headaches each month decreased from 4 days to 2 days.

Research into the benefits of riboflavin for migraines and pathogenically-related illnesses like Parkinson's disease have shown that riboflavin is neuroprotective through multiple mechanisms.¹⁰⁰ Specifically, riboflavin can improve oxidative stress, ameliorate mitochondrial cellular deficiencies, combat neuroinflammation, and reduce glutamate excitotoxicity.

Riboflavin offers its benefits at least in part through enzymes that rely on its presence. For example, riboflavin is required for methylenetetrahydrofolate reductase to ensure that the folate cycle has a normal influence on the methylation cycle. Without this regulation, homocysteine levels rise and negatively impact neurovascular functioning.^{101–103}

Mitochondrial dysfunction is believed to play a role in migraine pathophysiology, and the efficacy of riboflavin in migraine treatment may be due to its positive effect on mitochondrial metabolism.¹⁰⁴ Riboflavin, unlike coQ10, does indeed contribute to both the Krebs cycle and the mitochondrial electron transport chain.^{105,106} In fact, electron transport cannot function without riboflavin derivatives. Riboflavin generates ATP during glycolysis, which contributes to the Krebs cycle and then to the electron transport chain.¹⁰⁷

Feverfew

Feverfew, also known as *Tanacetum parthenium*, is often used medicinally for migraines as well as arthritis.¹⁰⁸ It has been hypothesized that the active ingredient of feverfew is parthenolide, which is contained in the leaves of feverfew.¹⁰⁹ However, when parthenolide is depleted from feverfew, the feverfew maintains its anti-inflammatory capabilities, suggesting that other compounds along with parthenolide are responsible for the therapeutic benefit of feverfew.¹¹⁰ Thus, subsequent analysis of phytochemical profiles for components of feverfew beyond parthenolide is necessary when extracting the herb. The absence of these other vital chemical compounds could explain why certain feverfew extracts do not generate any benefit.

Unlike many supplements that work only prophylactically or acutely in migraines, feverfew has been shown to decrease the frequency of migraines as well as their severity in more than 70% of migraine sufferers who have consumed it.¹⁰⁸

A randomized, double-blind, placebo-controlled study published in *The Lancet* has shown that 2 months of feverfew supplementation improved both the frequency and the severity of migraine attacks and that when taken for an additional 2 months, these benefits were further enhanced.¹¹¹

In many cases, the people who respond to feverfew have failed to respond to conventional treatments.¹⁰⁸ Some work suggests that feverfew extracts work through a mechanism that reduces the impact of CGRP, much the way that monoclonal antibodies have been designed to work. While there has long been anecdotal evidence for the advantages of using feverfew to combat migraines, double blind placebo-controlled trials have also demonstrated that those who take the herb experience reduced frequency and severity in migraines compared to those taking a placebo.

Research into the prophylactic value of feverfew has been promising. One randomized, double-blind, placebo-controlled study on 170 migraine sufferers showed that the number of migraine attacks per month decreased with feverfew consumption from nearly 5 attacks per month to fewer than 2 per month.¹¹²

The literature on the value of acute intervention with feverfew also paints a positive picture for the use of feverfew to treat migraines. One double-blind study showed that feverfew consumption reduced the severity of classic migraine symptoms, including pain, nausea, vomiting, and sensitivity to noise and light.¹¹³ The ability of feverfew extracts to function both prophylactically and acutely is likely due to its combination of anti-inflammatory benefits, CGRP benefits, and anti-platelet benefits.

Boswellia Serrata

Boswellia serrata, or Indian frankincense, has been used in Ayurvedic medicine for thousands of years.¹¹⁴ Its therapeutic value comes from its anti-inflammatory properties, which have been shown to be effective in patients with the inflammatory diseases like osteoarthritis and inflammatory bowel disease.^{115,116}

Boswellia serrata works through multiple pathways including the cyclooxygenase pathway. ¹¹⁷ It also inhibits 5-lipoxygenase enzyme activity.¹¹⁴

Though there is little data on the specific effects of *Boswellia serrata* on migraines, experts have suggested that this substance may be particularly helpful when used acutely for those with cluster and indomethacin-responsive headaches.¹¹⁸ The substance have also been shown to have a favorable safety profile.

Doses that have been shown to improve symptoms in patients with chronic cluster headaches ranged from 350 to 700 mg taken 3 times per day. *Boswellia serrata* was shown to reduce both the frequency and the intensity of the migraines.¹¹⁹ However, certain *Boswellia* extracts like Aflapin have been shown to have 5-lipoxygenase anti-inflammatory activity at doses as low as 100 mg per day. This dose has translated to clinically meaningful reductions in pain as well.¹²⁰

Ginger

For decades, ginger has been considered for its potential use to both prevent and treat migraines without unwanted side effects.¹²¹ Though ginger does not appear to confer prophylactic benefits against migraines, it does appear to be valuable when used acutely.^{122,123} A recent meta-analysis on the effects of ginger on migraine patients found that ginger improved pain and was associated with a reduced incidence of nausea and vomiting.¹²²

A study comparing the effects of ginger powder and a triptan (sumatriptan) found that the interventions were comparable in their efficacy for reducing headache severity.¹²⁴ Importantly, though, ginger had a superior profile in terms of side effects.

A double-blind placebo-controlled randomized clinical trial performed in a general hospital's emergency room showed that 400 mg of ginger extract that contained 5% active ingredient improved headaches within an hour of administration.¹²⁵

Melatonin

Though melatonin has been proposed as a potential treatment strategy in migraine, its benefits in migraine are likely due to its ability to improve sleep.¹²⁶ Sleep is indeed often dysfunctional in migraine, which may exacerbate symptoms. Improving sleep in those who suffer migraines may thus also improve migraine symptoms.

Corroborating this notion, for instance, is research into the effects of melatonin in pediatric migraine that showed that napping after treatment predicted greater improvements.¹²⁷ Further, melatonin has been shown to play a role in circadian rhythm regulation and sleep.¹²⁸ Though melatonin can have anti-inflammatory effects and scavenge free radicals, if its specific effects in migraine occur due to its impact on sleep, then improving sleep habits without the use of melatonin should be equally effective. It is possible that the value of melatonin for migraines extends beyond its influence on sleep due to multiple pleiotropic mechanisms.

Butterbur

Butterbur extract, which comes from the butterbur plant, *Petasites hybridus* has been suggested as a treatment for migraines, including in children.¹²⁹ Unfortunately, evidence has suggested that the use of butterbur could be associated with liver toxicity, which has led several countries, including the UK, Switzerland, and Italy to take butterbur products off the market.¹³⁰ Germany also retracted its approval of butterbur as a result, and the FDA currently does not approve butterbur for any indications.¹³¹ The toxicity may result from the pyrrolizidine alkaloids that butterbur leaves and stems can contain, which are known to be toxic to humans.¹³²

A recent update on the safety and efficacy of Petadolex, which is a butterbur extract, revealed that according to post-marketing surveillance of the product, data on Petadolex only supports its safety at lower doses, which led some European countries to withdraw the product.¹³³ The authors thus suggested that only lower doses and shorter treatment periods may be appropriate for the use of butterbur in migraines, severely limiting its potential value.

Though the American Academy of Neurology once recommended butterbur, it later retracted this recommendation based on the safety data.¹³¹ Given the efficacy of other ingredients like feverfew in combatting migraines, there is little reason to impose the risks associated with butterbur by incorporating it into a formulation aimed at addressing migraines.

CoQ10

Coenzyme Q10 (coQ10) is an electron carrier in the mitochondrial respiratory chain and is hydrophobic.¹³⁴ It serves as an antioxidant and has been observed to be deficient in adolescents and children with migraines.¹³⁵ These observations initially led to the notion that coQ10 supplementation may be beneficial in migraines. Today, the American Academy of Neurology recommends coQ10 supplementation for migraine prevention.¹³⁶

One double-blind, randomized, placebo-controlled trial involving 42 migraine patients showed that compared to those taking placebo, those taking 100 mg of coQ10 3 times per day had significantly less frequent migraine attacks, significantly fewer days with headaches, and significantly fewer days with nausea.¹³⁸ The frequency, severity, and duration of headache attacks were shown in another study to be reduced in women taking 400 mg/day of coQ10 when

compared to placebo.¹³⁹

One study that found that coQ10 as a monotherapy was comparable to placebo with respect to the level of migraine severity each day and the number of migraine attacks each month found that coQ10 was superior to placebo in reducing the number of migraine days each month.¹⁴⁰

Though coQ10 may offer some efficacy in combatting migraines, reducing frequency and duration of migraines, coQ10 also affects energy metabolism in a similar manner as riboflavin, making its effects potentially redundant in a formulation that already includes riboflavin.^{141,142}

In addition, some studies that point to the value of coQ10 in migraine prophylaxis have used coQ10 in combination with other potentially more beneficial substances like magnesium, feverfew, and riboflavin.¹⁴³ Given that these studies involved combination treatments, they have done little to clarify the efficacy of coQ10 as a monotherapy. Other CoQ10 studies used an open-label design, limiting the value of their results because of high rates of placebo effects that are observed in pain-related trials.

When coQ10 is studied as a monotherapy and shown to reduce the number of migraine days, the intervention fails to reduce the total number of migraines experienced. To reduce absolute number of headaches, studies include doses ranging from 300 mg to 600 mg per day, which greatly exceeds the doses in combination migraine supplements that tout migraine prophylactic capabilities.

Vitamin B12

There are multiple studies that have observed that migraine patients suffer vitamin B12 deficiencies.¹⁴⁴ Further, when children with low serum B12 have been given B12, their headache symptoms have resolved.¹⁴⁵

These observations have led to research to systematically study the potential therapeutic effect of cyanocobalamin - the substance used to treat vitamin B12 deficiency - in migraines. Though a small proportion of study participants appeared to benefit from cyanocobalamin in the initial studies, researchers concluded that there was no therapeutic effect of cyanocobalamin in migraines.¹⁴⁴

There has since been research on the specific effects of vitamin B12 in migraines, and a recent literature review on the utilization of vitamin B12 in chronic migraines concluded that vitamin B12 is a promising treatment for chronic migraines.¹⁴⁴ The vitamin acts as a cofactor for certain enzymes and converts homocysteine to methionine, which is critical for building essential proteins.^{144,146,147} Vitamin B12 may also affect migraines by scavenging nitric oxide.

Deficiencies in vitamin B12 are known to not only lead to dysregulation of the metabolism of methionine but to also manifest neurologically, resulting in fatigue, nerve damage, anemia, and developmental delay.^{144,148–150} Though data show that vitamin B12 supplementation may help combat migraine symptoms, the studies are limited, mainly because the research on the impact of vitamin B12 on migraine patients usually involves vitamin B12 supplementation along with other prophylactic interventions, making it difficult to tease out the specific effects of vitamin B12.¹⁴⁴ The current evidence for a therapeutic role of vitamin B12 in migraines is thus weak. Given the contradictions in the literature, more research is needed to determine if vitamin B12 can offer value to migraine patients.

Folic Acid

Folic acid can act as a vasodilator for small arteries, suggesting it could be an effective intervention for migraines.¹⁵¹ Research on the effects of folic acid on women with migraines showed an inverse relationship between folate consumption and migraine frequency, suggesting that folate intake may affect migraine frequency in female migraineurs.¹⁵²

Its use as a slow intravenous injectable at a dose of 15 mg has led to reduced headache intensity within an hour on average following injection for about 60% of patients.¹⁵¹ A second injection was given to those who still felt head pain the following day, and the majority of patients responded to this second dose. Pulse wave studies showed that the folic acid therapy restored elasticity in the involved artery and reduced relevant edema. However, folic acid injections were less effective in older patients and were also associated with some side effects including nausea and vomiting. Overall, studies on folic acid in migraines are contradictory and show weak evidence for its value.

CONCLUSION

Migraines present a medical challenge for patients and healthcare providers, with none of the conventional treatment options offering a reliable, long-term, safe solution that works for migraine symptoms. Though often tedious, trial-and-error is often a necessary process for individual migraine patients to determine the best way to deal with their symptoms. For those who have not tried pharmacological interventions or for whom migraine drugs do not work or cause unwanted side effects, supplements that combine ingredients that have been shown to have potentially beneficial effects in migraine patients may be a good first or next step, respectively.

For those interested in such an approach, committing to a 3-month regimen can help to determine any potential impact of a supplement and provide actionable insights for patients and their healthcare providers. Given that feverfew, riboflavin, and magnesium have well-established prophylactic effects against migraines and favorable safety profiles, a migraine supplement that includes these ingredients could help migraineurs circumvent pharmacological interventions while still achieving symptom relief.

References

1. Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants. *Journal of the Neurological Sciences*. 2017;372:307-315. doi:10.1016/j.jns.2016.11.071
2. Feigin VL, Krishnamurthi R v., Theadom AM, et al. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet Neurology*. 2017;16(11):877-897. doi:10.1016/S1474-4422(17)30299-5
3. Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet*. 2016;388(10053):1545-1602. doi:10.1016/S0140-6736(16)31678-6
4. Dodick DW. Migraine. *The Lancet*. 2018;391(10127):1315-1330. doi:10.1016/S0140-6736(18)30478-1
5. MacGregor EA. Migraine. *Annals of internal medicine*. 2017;166(7):ITC49-ITC64. doi:10.7326/AITC201704040
6. Migraine Facts - Migraine Research Foundation. Accessed January 25, 2021. <https://migraineresearchfoundation.org/about-migraine/migraine-facts/>
7. Buse DC, Scher AI, Dodick DW, et al. Impact of Migraine on the Family: Perspectives of People with Migraine and Their Spouse/Domestic Partner in the CaMEO Study. *Mayo Clinic Proceedings*. 2016;91(5):596-611. doi:10.1016/j.mayocp.2016.02.013
8. Kelman L. Pain characteristics of the acute migraine attack. *Headache*. 2006;46(6):942-953. doi:10.1111/j.1526-4610.2006.00443.x
9. Eross E, Dodick D, Eross M. The Sinus, Allergy and Migraine Study (SAMS): CME. *Headache*. 2007;47(2):213-224. doi:10.1111/j.1526-4610.2006.00688.x
10. Lipton RB, Silberstein SD. Episodic and chronic migraine headache: Breaking down barriers to optimal treatment and prevention. *Headache*. 2015;55(52):103-122. doi:10.1111/head.12505_2

11. Silberstein SD. Migraine Symptoms: Results of a Survey of Self-Reported Migraineurs. *Headache: The Journal of Head and Face Pain*. 1995;35(7):387-396. doi:10.1111/j.1526-4610.1995.hed3507387.x
12. Russel MB, Olesen J. A nosographic analysis of the migraine aura in a general population. *Brain*. 1996;119(2):355-361. doi:10.1093/brain/119.2.355
13. Calhoun AH, Ford S, Millen C, Finkel AG, Truong Y, Nie Y. The prevalence of neck pain in migraine. *Headache*. 2010;50(8):1273-1277. doi:10.1111/j.1526-4610.2009.01608.x
14. Bigal ME, Ashina S, Burstein R, et al. Prevalence and characteristics of allodynia in headache sufferers: A population study. *Neurology*. 2008;70(17):1525-1533. doi:10.1212/01.wnl.0000310645.31020.b1
15. Selby, G. & Lance, JW. Observations on 500 cases of migraine and allied vascular headache. *Journal of neurology, neurosurgery, and psychiatry*. 1960;23(1):23-32. doi:10.1136/jnnp.23.1.23
16. Friedman DI, Evans RW. Are Blurred Vision and Short-Duration Visual Phenomena Migraine Aura Symptoms? *Headache*. 2017;57(4):643-647. doi:10.1111/head.13042
17. Kelman L. The place of osmophobia and taste abnormalities in migraine classification: A tertiary care study of 1237 patients. *Cephalalgia*. 2004;24(11):940-946. doi:10.1111/j.1468-2982.2004.00766.x
18. Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: An electronic diary study. *Neurology*. 2003;60(6):935-940. doi:10.1212/01.WNL.0000052998.58526.A9
19. Karsan N, Prabhakar P, Goadsby PJ. Characterising the premonitory stage of migraine in children: a clinic-based study of 100 patients in a specialist headache service. *Journal of Headache and Pain*. 2016;17(1). doi:10.1186/s10194-016-0689-7
20. Giffin NJ, Lipton RB, Silberstein SD, Olesen J, Goadsby PJ. The migraine prodrome. *Neurology*. 2016;87(3):309-313. doi:10.1212/WNL.0000000000002789
21. Kelman L. The prodrome of the acute migraine attack. *Cephalalgia*. 2006;26(2):214-220. doi:10.1111/j.1468-2982.2005.01026.x
22. Quintela E, Castillo J, Muñoz P, Pascual J. Premonitory and resolution symptoms in migraine: A prospective study in 100 unselected patients. *Cephalalgia*. 2006;26(9):1051-1060. doi:10.1111/j.1468-2982.2006.01157.x
23. Karsan N, Pérez-Rodríguez A, Nagaraj K, Bose PR, Goadsby PJ. The migraine prodrome: Spontaneous and triggered phenotypes. *Cephalalgia*. 2021;41(6):721-730. doi:10.1177/0333102420975401
24. Gori S, Lucchesi C, Baldacci F, Bonuccelli U. Preferential occurrence of attacks during night sleep and/or upon awakening negatively affects migraine clinical presentation. *Functional Neurology*. 2015;30(2):119-123. doi:10.1138/FNeur/2015.30.2.119
25. Kelman L, Rains JC. Headache and sleep: Examination of sleep patterns and complaints in a large clinical sample of migraineurs. *Headache*. 2005;45(7):904-910. doi:10.1111/j.1526-4610.2005.05159.x
26. Migraine Treatment: What's Old, What's New. Accessed January 25, 2021. https://www.practicalpainmanagement.com/pain/headache/migraine/migraine-treatment-what-old-what-new?page=0_3
27. Sutherland HG, Albury CL, Griffiths LR. Advances in genetics of migraine. *Journal of Headache and Pain*. 2019;20(1). doi:10.1186/s10194-019-1017-9
28. Burch R, Rizzoli P, Loder E. The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies. *Headache*. 2018;58(4):496-505. doi:10.1111/head.13281
29. Bille B. A 40-year follow-up of school children with migraine. *Cephalalgia*. 1997;17(4):488-491. doi:10.1046/j.1468-2982.1997.1704488.x
30. Yeh WZ, Blizzard L, Taylor B v. What is the actual prevalence of migraine? *Brain and Behavior*. 2018;8(6). doi:10.1002/brb3.950
31. Lipton RB, Stewart WF, Stone AM, Láinez MJA, Sawyer JPC. Stratified care vs step care strategies for migraine: The disability in strategies of care (DISC) study: A randomized trial. *Journal of the American Medical Association*. 2000;284(20):2599-2605. doi:10.1001/jama.284.20.2599
32. Becker WJ. Acute migraine treatment in adults. *Headache*. 2015;55(6):778-793. doi:10.1111/head.12550
33. Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine: Results of a randomized, double-blind, placebo-controlled, population-based study. *Archives of Internal Medicine*. 2000;160(22):3486-3492. doi:10.1001/archinte.160.22.3486
34. Prior MJ, Codispoti JR, Fu M. A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache. *Headache*. 2010;50(5):819-833. doi:10.1111/j.1526-4610.2010.01638.x
35. McCrae JC, Morrison EE, MacIntyre IM, Dear JW, Webb DJ. Long-term adverse effects of paracetamol – a review. *British Journal of Clinical Pharmacology*. 2018;84(10):2218-2230. doi:10.1111/bcp.13656
36. Suthisisang CC, Poolsup N, Suksomboon N, Lertpipometha V, Tepwitukgid B. Meta-Analysis of the Efficacy and Safety of Naproxen Sodium in the Acute Treatment of Migraine. *Headache: The Journal of Head and Face Pain*. 2010;50(5):808-818. doi:10.1111/j.1526-4610.2010.01635.x
37. Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. *Biochemical Pharmacology*. 2020;180. doi:10.1016/j.bcp.2020.114147
38. Bjarnason I, Hayllar J, Macpherson AN drew J, Russell AN thony S. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. *Gastroenterology*. 1993;104(6):1832-1847. doi:10.1016/0016-5085(93)90667-2
39. Davis A, Robson J. The dangers of NSAIDs: Look both ways. *British Journal of General Practice*. 2016;66(645):172-173. doi:10.3399/bjgp16X684433
40. Eadie MJ. Ergot of rye - The first specific for migraine. *Journal of Clinical Neuroscience*. 2004;11(1):4-7. doi:10.1016/j.jocn.2003.05.002
41. Baron EP, Tepper SJ. Revisiting the role of ergots in the treatment of migraine and headache. *Headache*. 2010;50(8):1353-1361. doi:10.1111/j.1526-4610.2010.01662.x
42. Bozoghlanian M, Vasudevan S v. Overview of migraine treatment. *Pain Management*. 2012;2(4):399-414. doi:10.2217/pmt.12.29
43. Whyte CA, Tepper SJ. Adverse effects of medications commonly used in the treatment of migraine. *Expert Review of Neurotherapeutics*. 2009;9(9):1379-1391. doi:10.1586/ern.09.47
44. Xu H, Han W, Wang J, Li M. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. *Journal of Headache and Pain*. 2016;17(1):1-18. doi:10.1186/s10194-016-0703-0
45. de Felice M, Ossipov MH, Wang R, et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. *Annals of Neurology*. 2010;67(3):325-337. doi:10.1002/ana.21897
46. Lacroix I, Hurault-Delarue C, Viard D, Revol B, Chaalal L, Damase-Michel C. Use of triptans during pregnancy? With caution! *Therapie*. Published online 2020. doi:10.1016/j.therap.2019.12.007
47. Shimizu T. Beta blockers in migraine prophylaxis. *Brain Nerve*. 2009;61(10):1125-

- 1130. Accessed May 23, 2021. <https://pubmed.ncbi.nlm.nih.gov/19882938/>
48. Holroyd KA, Cottrell CK, O'Donnell FJ, et al. Effect of preventive (β blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: Randomised controlled trial. *BMJ* (Online). 2010;341(7776):769. doi:10.1136/bmj.c4871
 49. Koella WP. CNS-related (side-)effects of β -Blockers with special reference to mechanisms of action. *European Journal of Clinical Pharmacology*. 1985;28(1 Supplement):55-63. doi:10.1007/BF00543711
 50. McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. *Pharmacology and Therapeutics*. 1990;46(2):163-197. doi:10.1016/0163-7258(90)90092-G
 51. Rogawski MA. Common pathophysiologic mechanisms in migraine and epilepsy. *Archives of Neurology*. 2008;65(6):709-714. doi:10.1001/archneur.65.6.709
 52. Marmura MJ, Kumpinsky AS. Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders. *CNS Drugs*. 2018;32(8):735-746. doi:10.1007/s40263-018-0555-z
 53. Mulleners WM, McCrory DC, Linde M. Antiepileptics in migraine prophylaxis: An updated Cochrane review. *Cephalalgia*. 2015;35(1):51-62. doi:10.1177/0333102414534325
 54. Shahien R, Beirut K. Preventive Agents for Migraine: Focus on the Antiepileptic Drugs. *Journal of Central Nervous System Disease*. 2012;4:jCNSD.S9049. doi:10.4137/jcnsd.s9049
 55. Romoli M, Siliquini S, Corbelli I, et al. O064. Antiepileptic drugs in migraine and epilepsy disorders: who is at increased risk of adverse events? *Journal of Headache and Pain*. 2015;16(Suppl 1):1-2. doi:10.1186/1129-2377-16-S1-A69
 56. Mathew NT. Antiepileptic drugs in migraine prevention. *Headache*. 2001;41(SUPPL. 1):18-25. doi:10.1046/j.1526-4610.2001.01154-4.x
 57. Cramer JA, Mintzer S, Whelles J, Mattson RH. Adverse effects of antiepileptic drugs: A brief overview of important issues. *Expert Review of Neurotherapeutics*. 2010;10(6):885-891. doi:10.1586/ern.10.71
 58. Chen B, Detyniecki K, Choi H, et al. Psychiatric and behavioral side effects of anti-epileptic drugs in adolescents and children with epilepsy. *European Journal of Paediatric Neurology*. 2017;21(3):441-449. doi:10.1016/j.ejpn.2017.02.003
 59. Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. *Epilepsy and Behavior*. 2017;76:24-31. doi:10.1016/j.yebeh.2017.08.039
 60. Glover V, Jarman J, Sandler M. Migraine and depression: Biological aspects. *Journal of Psychiatric Research*. 1993;27(2):223-231. doi:10.1016/0022-3956(93)90010-Y
 61. Ligthart L, Gerrits MMJG, Boomsma DI, Penninx BWJH. Anxiety and depression are associated with migraine and pain in general: An investigation of the interrelationships. *Journal of Pain*. 2013;14(4):363-370. doi:10.1016/j.jpain.2012.12.006
 62. Wacogne C, Lacoste JP, Guilibert E, Hugues FC, le Jeune C. Stress, anxiety, depression and migraine. *Cephalalgia*. 2003;23(6):451-455. doi:10.1046/j.1468-2982.2003.00550.x
 63. Koch HJ, Jürgens TP. Antidepressants in long-term migraine prevention. *Drugs*. 2009;69(1):1-19. doi:10.2165/0003495-200969010-00001
 64. Koch HJ, Jürgens TP. Antidepressants in long-term migraine prevention. *Drugs*. 2009;69(1):1-19. doi:10.2165/0003495-200969010-00001
 65. Migraine medications and antidepressants: A risky mix? - Mayo Clinic. Accessed May 31, 2021. <https://www.mayoclinic.org/diseases-conditions/migraine-headache/expert-answers/migraine-medications/faq-20058166>
 66. Ferguson JM. SSRI antidepressant medications: Adverse effects and tolerability. *Primary Care Companion to the Journal of Clinical Psychiatry*. 2001;3(1):22-27. doi:10.4088/pcc.v03n0105
 67. Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. <https://doi.org/10.1080/14712598.2019.1671350>. 2019;19(12):1307-1317. doi:10.1080/14712598.2019.1671350
 68. [Novel migraine treatment with CGRP-related monoclonal antibodies]. | *Physician's Weekly*. Accessed August 30, 2021. <https://www.physiciansweekly.com/novel-migraine-treatment-with-cgrp-related-monoclonal-antibodies/>
 69. Ibekwe A, Perras C, Mierzynski-Urban M. Monoclonal Antibodies to Prevent Migraine Headaches. *CADTH Issues in Emerging Health Technologies*. Published online February 1, 2018. Accessed August 30, 2021. <https://www.ncbi.nlm.nih.gov/books/NBK538376/>
 70. Wang X, Chen Y, Song J, You C. Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis. *Frontiers in Pharmacology*. 2021;12. doi:10.3389/fphar.2021.649143
 71. Deng H, Li G gai, Nie H, et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis. *BMC Neurology* 2020 20:1. 2020;20(1):1-12. doi:10.1186/S12883-020-01633-3
 72. Lu J, Zhang Q, Guo X, et al. Calcitonin Gene-Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison. *Frontiers in Pharmacology*. 2021;12:631204. doi:10.3389/fphar.2021.631204
 73. Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD. Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis. <https://doi.org/10.1177/0333102421989601>. 2021;41(7):851-864. doi:10.1177/0333102421989601
 74. CGRP Monoclonal Antibodies for Chronic Migraine Prevention: Evaluation of Adverse Effects. Accessed November 29, 2021. <https://www.practicalpainmanagement.com/treatments/pharmacological/cgrp-monoclonal-antibodies-chronic-migraine-prevention-evaluation-adverse>
 75. Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD. Chronic migraine - Classification, characteristics and treatment. *Nature Reviews Neurology*. 2012;8(3):162-171. doi:10.1038/nrneuro.2012.13
 76. Cupini LM, Calabresi P. Medication-overuse headache: Pathophysiological insights. *Journal of Headache and Pain*. 2005;6(4):199-202. doi:10.1007/s10194-005-0184-z
 77. Katsarava Z, Obermann M. Medication-overuse headache. *Current Opinion in Neurology*. 2013;26(3):276-281. doi:10.1097/WCO.0b013e328360d596
 78. Hindiyeh NA, Zhang N, Farrar M, Banerjee P, Lombard L, Aurora SK. The Role of Diet and Nutrition in Migraine Triggers and Treatment: A Systematic Literature Review. *Headache*. 2020;60(7):1300-1316. doi:10.1111/head.13836
 79. Bahra A. Primary Headache Disorders: Focus on Migraine. *Reviews in Pain*. 2011;5(4):2-11. doi:10.1177/204946371100500402
 80. Razeghi Jahromi S, Ghorbani Z, Martelletti P, Lampi C, Togha M. Association of diet and headache. *Journal of Headache and Pain*. 2019;20(1):106. doi:10.1186/s10194-019-1057-1
 81. Chen L, Zhang Z, Chen W, Whelton PK, Appel LJ. Lower sodium intake and risk of headaches: Results from the trial of Nonpharmacologic Interventions in the Elderly. *American Journal of Public Health*. 2016;106(7):1270-1275. doi:10.2105/AJPH.2016.303143
 82. Amer M, Woodward M, Appel LJ. Effects of dietary sodium and the DASH diet on the occurrence of headaches: Results from randomised multicentre DASH-Sodium clinical trial. *BMJ Open*. 2014;4(12):e6671. doi:10.1136/bmjopen-2014-006671
 83. Varkey E, Cider A, Carlsson J, Linde M. Exercise as migraine prophylaxis: A randomized study using relaxation and topiramate as controls. *Cephalalgia*. 2011;31(14):1428-1438. doi:10.1177/0333102411419681
 84. Irby MB, Bond DS, Lipton RB, Nicklas B, Houle TT, Penzien DB. Aerobic Exercise for Reducing Migraine Burden: Mechanisms, Markers, and Models of Change Processes. *Headache*. 2016;56(2):357-369. doi:10.1111/head.12738
 85. Amin FM, Aristeidou S, Baraldi C, et al. The association between migraine and physical exercise. *The Journal of Headache and Pain*. 2018;19(1):83. doi:10.1186/s10194-018-0902-y
 86. Ahn AH. Why does increased exercise decrease migraine? *Current Pain and Headache Reports*. 2013;17(12). doi:10.1007/s11916-013-0379-y
 87. The role of exercise in migraine treatment - PubMed. Accessed May 31, 2021. <https://pubmed.ncbi.nlm.nih.gov/24921618/>
 88. Lemmens J, de Pauw J, van Soom T, et al. The effect of aerobic exercise on the number of migraine days, duration and pain intensity in migraine: a systematic literature review and meta-analysis. *The Journal of Headache and Pain*. 2019;20(1):16. doi:10.1186/s10194-019-0961-8
 89. Sharpe L, Dudeney J, Williams AC de C, et al. Psychological therapies for the prevention of migraine in adults. *Cochrane Database of Systematic Reviews*. 2019;2019(7). doi:10.1002/14651858.CD012925.pub2
 90. Tepper SJ. Nutraceutical and other modalities for the treatment of headache. *Continuum Lifelong Learning in Neurology*. 2015;21(4):1018-1031. doi:10.1212/CON.0000000000000211
 91. Kropp P, Meyer B, Meyer W, Dresler T. An update on behavioral treatments in migraine – current knowledge and future options. *Expert Review of Neurotherapeutics*. 2017;17(11):1059-1068. doi:10.1080/14737175.2017.1377611
 92. Dolati S, Rikhtegar R, Mehdizadeh A, Yousefi M. The Role of Magnesium in Pathophysiology and Migraine Treatment. *Biological Trace Element Research*. 2020;196(2):375-383. doi:10.1007/s12011-019-01931-z
 93. Taylor FR. Nutraceuticals and headache: The biological basis. *Headache*. 2011;51(3):484-501. doi:10.1111/j.1526-4610.2011.01847.x
 94. Dolati S, Rikhtegar R, Mehdizadeh A, Yousefi M. The Role of Magnesium in Pathophysiology and Migraine Treatment. *Biological Trace Element Research*. 2020;196(2):375-383. doi:10.1007/s12011-019-01931-z
 95. Sun-Edelstein C, Mauskop A. Role of magnesium in the pathogenesis and treatment of migraine. *Expert Review of Neurotherapeutics*. 2009;9(3):369-379. doi:10.1586/14737175.9.3.369
 96. Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: Results from a prospective, multi-center, placebo-controlled and double-blind randomized study. *Cephalalgia*. 1996;16(4):257-263. doi:10.1046/j.1468-2982.1996.1604257.x
 97. Demirkaya Ş, Vural O, Dora B, Topçuoğlu MA. Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. *Headache*. 2001;41(2):171-177. doi:10.1046/j.1526-4610.2001.111006171.x
 98. Namazi N, Heshmati J, Tarighat-Esfanjani A. Supplementation with riboflavin (vitamin B2) for migraine prophylaxis in adults and children: A review. *International Journal for Vitamin and Nutrition Research*. 2015;85(1-2):79-87. doi:10.1024/0300-9831/a000225
 99. Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhä KM, Arnold G. High-Dose Riboflavin Treatment Is Efficacious in Migraine Prophylaxis: An Open Study in a Tertiary Care Centre.
 100. Sassone J, Pessia M, Marashly ET, Bohlega SA. Riboflavin Has Neuroprotective Potential: Focus on Parkinson's Disease and Migraine. *Article*. 2017;8:1. doi:10.3389/fneur.2017.00333
 101. Strain JJ, Dowe L, Ward M, Pentieva K, McNulty H. B-vitamins, homocysteine metabolism and CVD. *Proceedings of the Nutrition Society*. 2004;63(4):597-603. doi:10.1079/pns2004390
 102. McCully KS. Homocysteine, vitamins, and vascular disease prevention. In: *American Journal of Clinical Nutrition*. Vol 86. American Society for Nutrition; 2007:1563S-1568S. doi:10.1093/ajcn/86.5.1563s
 103. Lippi G, Mattiuzzi C, Meschi T, Cervellin G, Borghi L. Homocysteine and migraine. A narrative review. *Clinica Chimica Acta*. 2014;433:5-11. doi:10.1016/j.cca.2014.02.028
 104. Yorns WR, Hardison HH. Mitochondrial dysfunction in migraine. *Seminars in Pediatric Neurology*. 2013;20(3):188-193. doi:10.1016/j.spen.2013.09.002
 105. Riboflavin - an overview | ScienceDirect Topics. Accessed June 6, 2021. <https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/riboflavin>
 106. Pinto JT, Zemljeni J. Riboflavin. *Advances in Nutrition*. 2016;7(5):973-975. doi:10.3945/an.116.012716
 107. Fox IS. Riboflavin deficiency. *British Medical Journal*. 1942;2(4274):678. doi:10.1136/bmj.2.4274.678-b
 108. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. *British Medical Journal (Clinical research ed)*. 1985;291(6495):569-573. doi:10.1136/bmj.291.6495.569
 109. Feverfew - PubMed. Accessed January 25, 2021. <https://pubmed.ncbi.nlm.nih.gov/30000921/>
 110. Sur R, Martin K, Liebel F, Lyte P, Shapiro S, Southall M. Anti-inflammatory activity of parthenolide-depleted feverfew (*Tanacetum parthenium*). *Inflammopharmacology*. 2009;17(1):42-49. doi:10.1007/s10787-008-8040-9
 111. Murphy JJ, Heptinstall S, Mitchell JRA. RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF FEVERFEW IN MIGRAINE PREVENTION. *The Lancet*. 1988;332(8604):189-192. doi:10.1016/S0140-6736(88)92289-1
 112. Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-Von Zepelin HH. Efficacy and safety of 6.25 mg t.i.d. feverfew CO₂-extract (MIG-99) in migraine prevention - A randomized, double-blind, multicentre, placebo-controlled study. *Cephalalgia*. 2005;25(11):1031-1041. doi:10.1111/j.1468-2982.2005.00950.x
 113. Palevitch D, Earon G, Carasso R. Feverfew (*Tanacetum parthenium*) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. *Phytotherapy Research*. 1997;11(7):508-511. doi:10.1002/(SICI)1099-1573(199711)11:7<508::AID-PTR153-3.0.CO;2-H

114. *Boswellia serrata* - an overview | ScienceDirect Topics. Accessed May 20, 2021. <https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/boswellia-serrata>
115. Yu C, Xiang W, Zhang T, Zeng L, Yang K, Li J. Effectiveness of *Boswellia* and *Boswellia* extract for osteoarthritis patients: a systematic review and meta-analysis. *BMC complementary medicine and therapies*. 2020;20(1):225. doi:10.1186/s12906-020-02985-6
116. Catanzaro D, Rancan S, Orso G, et al. *Boswellia serrata* preserves intestinal epithelial barrier from oxidative and inflammatory damage. *PLoS ONE*. 2015;10(5). doi:10.1371/journal.pone.0125375
117. Shelmadine BD, Bowden RG, Moreillon JJ, et al. A Pilot Study to Examine the Effects of an Anti-inflammatory Supplement on Eicosanoid Derivatives in Patients with Chronic Kidney Disease. *Journal of alternative and complementary medicine* (New York, NY). 2017;23(8):632-638. doi:10.1089/acm.2016.0007
118. Expert Answer: *Boswellia* As A Potential Herbal Remedy. Accessed May 20, 2021. <https://migraine.com/blog/boswellia-a-potential-herbal-remedy>
119. Lampl C, Haider B, Schweiger C. Long-term efficacy of *Boswellia serrata* in four patients with chronic cluster headache. *Cephalalgia*. 2012;32(9):719-722. doi:10.1177/0333102412451357
120. Vishal AA, Mishra A, Raychaudhuri SP. A Double Blind, Randomized, Placebo Controlled Clinical Study Evaluates the Early Efficacy of Aflapin® in Subjects with Osteoarthritis of Knee. *International Journal of Medical Sciences*. 2011;8(7):615. doi:10.7150/IJMS.8.615
121. Mustafa T, Srivastava KC. Ginger (*zingiber officinale*) in migraine headache. *Journal of Ethnopharmacology*. 1990;29(3):267-273. doi:10.1016/0378-8741(90)90037-T
122. Chen L, Cai Z. The efficacy of ginger for the treatment of migraine: A meta-analysis of randomized controlled studies. *American Journal of Emergency Medicine*. Published online 2020. doi:10.1016/j.ajem.2020.11.030
123. Martins LB, Rodrigues AM dos S, Monteze NM, et al. Double-blind placebo-controlled randomized clinical trial of ginger (*Zingiber officinale* Rosc.) in the prophylactic treatment of migraine. *Cephalalgia*. 2020;40(1):88-95. doi:10.1177/0333102419869319
124. Maghbooli M, Golipour F, Moghimi Esfandabadi A, Yousefi M. Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine. *Phytotherapy Research*. 2014;28(3):412-415. doi:10.1002/ptr.4996
125. Martins LB, Rodrigues AM dos S, Rodrigues DF, dos Santos LC, Teixeira AL, Ferreira AVM. Double-blind placebo-controlled randomized clinical trial of ginger (*Zingiber officinale* Rosc.) addition in migraine acute treatment. *Cephalalgia*. 2019;39(1):68-76. doi:10.1177/0333102418776016
126. Song TJ, Kim BS, Chu MK. Therapeutic role of melatonin in migraine prophylaxis: Is there a link between sleep and migraine? In: *Progress in Brain Research*. Vol 255. Elsevier B.V.; 2020:343-369. doi:10.1016/bs.pbr.2020.05.014
127. Gelfand AA, Ross AC, Irwin SL, Greene KA, Qubty WF, Allen IE. Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial. *Headache*. 2020;60(8):1712-1721. doi:10.1111/head.13934
128. Peres MFP. Melatonin, the pineal gland and their implications for headache disorders. *Cephalalgia*. 2005;25(6):403-411. doi:10.1111/j.1468-2982.2005.00889.x
129. Utterback G, Zacharias R, Timraz S, Mershman D. Butterbur extract: Prophylactic treatment for childhood migraines. *Complementary Therapies in Clinical Practice*. 2014;20(1):61-64. doi:10.1016/j.ctcp.2012.04.003
130. Butterbur | NCCIH. Accessed May 23, 2021. <https://www.nccih.nih.gov/health/butterbur>
131. Butterbur Article. Accessed June 6, 2021. https://www.statpearls.com/articlelibrary/viewarticle/18735/#ref_26954394
132. Butterbur - LiverTox - NCBI Bookshelf. Accessed June 6, 2021. <https://www.ncbi.nlm.nih.gov/books/NBK547997/>
133. Prieto JM. Update on the efficacy and safety of Petadolex® and a butterbur extract for migraine prophylaxis. *Botanics: Targets and Therapy*. 2014;4:1. doi:10.2147/btat.s54023
134. Pucci E, Diamanti L, Cristina S, Antonaci F, Costa A. P032. Coenzyme Q-10 and migraine: a lovable relationship. The experience of a tertiary headache center. *The Journal of Headache and Pain*. 2015;16(S1). doi:10.1186/1129-2377-16-s1-a139
135. Hershey AD, Powers SW, Vockell ALB, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. *Headache*. 2007;47(1):73-80. doi:10.1111/j.1526-4610.2007.00652.x
136. Testai L, Martelli A, Flori L, Colletti A, Cicero AFG. Coenzyme q10: Clinical applications beyond cardiovascular diseases. *Nutrients*. 2021;13(5). doi:10.3390/NU13051697
137. Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. *Cephalalgia*. 2002;22(2):137-141. doi:10.1046/j.1468-2982.2002.00335.x
138. Sándor PS, Clemente L di, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. *Neurology*. 2005;64(4):713-715. doi:10.1212/01.WNL.0000151975.03598.ED
139. Dahri M, Hashemilar M, Asghari-Jafarabadi M, Tarighat-Esfanjani A. Efficacy of coenzyme Q10 for the prevention of migraine in women: A randomized, double-blind, placebo-controlled study. *European Journal of Integrative Medicine*. 2017;16:8-14. doi:10.1016/j.eujim.2017.10.003
140. Zeng Z, Li Y, Lu S, Huang W, Di W. Efficacy of CoQ10 as supplementation for migraine: A meta-analysis. *Acta Neurologica Scandinavica*. 2019;139(3):284-293. doi:10.1111/ANE.13051
141. Sándor PS, di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. *Neurology*. 2005;64(4):713-715. doi:10.1212/01.WNL.0000151975.03598.ED
142. Sazali S, Badrin S, Norhayati MN, Idris NS. Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine - A meta-analysis. *BMJ Open*. 2021;11(1):39358. doi:10.1136/bmjopen-2020-039358
143. Guilbot A, Bangratz M, Ait Abdellah S, Lucas C. A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: A prospective observational study. *BMC Complementary and Alternative Medicine*. 2017;17(1). doi:10.1186/s12906-017-1933-7
144. Urits I, Yilmaz M, Bahrnun E, et al. Utilization of B12 for the treatment of chronic migraine. *Best Practice and Research: Clinical Anaesthesiology*. 2020;34(3):479-491. doi:10.1016/j.bpa.2020.07.009
145. Calik M, Aktas MS, Cecen E, et al. The association between serum vitamin B12 deficiency and tension-type headache in Turkish children. *Neurological Sciences*. 2018;39(6):1009-1014. doi:10.1007/s10072-018-3286-5
146. L. Neeb, U. Reuter. Nitric Oxide in Migraine. *CNS & Neurological Disorders - Drug Targets*. 2008;6(4):258-264. doi:10.2174/187152707781387233
147. Nattagh-Eshativani E, Sani MA, Dahri M, et al. The role of nutrients in the pathogenesis and treatment of migraine headaches: Review. *Biomedicine and Pharmacotherapy*. 2018;102:317-325. doi:10.1016/j.biopha.2018.03.059
148. Miya Shaik M, Lin Tan H, A Kamal M, Hua Gan S. Do Folate, Vitamins B6 and B12 Play a Role in the Pathogenesis of Migraine? The Role of Pharmacopigenomics.
149. Rasmussen SA, Fernhoff PM, Scanlon KS. Vitamin B12 deficiency in children and adolescents. *Journal of Pediatrics*. 2001;138(1):10-17. doi:10.1067/mpd.2001.112160
150. Shaik MM, Gan SH. Vitamin supplementation as possible prophylactic treatment against migraine with aura and menstrual migraine. *BioMed Research International*. 2015;2015. doi:10.1155/2015/469529
151. Kojas, TL. The use of folic acid in vascular headache of the migraine type. *Headache: The Journal of Head and Face Pain*. 1969;8(4):167-170. doi:10.1111/j.1526-4610.1969.hed0804167.x
152. Menon S, Lea RA, Ingle S, et al. Effects of dietary folate intake on migraine disability and frequency. *Headache*. 2015;55(2):301-309. doi:10.1111/head.12490